Literature DB >> 27311071

Adherence and quality of care in IBD.

Palle Bager1, Mette Julsgaard1, Thea Vestergaard1, Lisbet Ambrosius Christensen1, Jens Frederik Dahlerup1.   

Abstract

OBJECTIVE: In inflammatory bowel disease (IBD), adherence to both medical treatment and other aspects of care has a substantial impact on the course of the disease. Most studies of medical adherence have reported that 30-45% of patients with IBD were non-adherent. Our study aimed to investigate the different aspects of adherence and to identify predictors of non-adherence, including the quality of care, for outpatients with IBD.
MATERIALS AND METHODS: An anonymous electronic questionnaire was used to investigate different aspects of adherence, the quality of care, patient involvement and shared decision making among 377 IBD outpatients.
RESULTS: Three hundred (80%) filled in the questionnaire. The overall adherence rate was 93%. Young age (< 35 years old) and smoking were significantly associated with non-adherence (prevalence odds ratio (POR) 2.98, 95% CI 1.04-8.52, p < 0.05 and POR 3.88, 95% CI 1.36-11.05, p < 0.05, respectively). The lowest medical adherence rates were found for 5-ASA and topical treatments among patients with inactive disease. A large majority of patients stated that treatment strategies were agreed upon as a shared decision between the patient and the health care professionals.
CONCLUSIONS: Predictors for non-adherence were young age and smoking. High adherence rates could be explained by a high patient satisfaction and a high degree of shared decision making.

Entities:  

Keywords:  Adherence; Crohn’s disease; decision making; inflammatory bowel disease; patient compliance; quality of health care; ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27311071     DOI: 10.1080/00365521.2016.1195870

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores.

Authors:  Eva-Maria Messner; Niklas Sturm; Yannik Terhorst; Lasse B Sander; Dana Schultchen; Alexandra Portenhauser; Simone Schmidbaur; Michael Stach; Jochen Klaus; Harald Baumeister; Benjamin M Walter
Journal:  J Med Internet Res       Date:  2022-10-05       Impact factor: 7.076

2.  Patients Prioritize a Low-volume Bowel Preparation in Colitis-associated Colorectal Cancer Surveillance: A Discrete Choice Experiment.

Authors:  Anouk M Wijnands; Maarten Te Groen; Yonne Peters; Ad A Kaptein; Bas Oldenburg; Frank Hoentjen; Maurice W M D Lutgens
Journal:  Inflamm Bowel Dis       Date:  2022-07-01       Impact factor: 7.290

3.  Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study.

Authors:  Alessandra Guarini; Silvia Biagini; Antonella Capaldi; Daniela Carretto; Anna De Angelis; Salvatore Iudice; Giuseppina Martino; Barbara Marziali; Roberta Mattiola; Cristina Ongarelli; Francesca Maria Onidi; Manuela Prinzio; Reetha Puthiavettil; Romina Sardi; Elisa Schiavoni; Rita Sinatora; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2016-10-27

4.  Factors Predicting the Adherence to the Therapy of Italian IBD Patients.

Authors:  Cristina Bucci; Fabiana Zingone; Stella Tammaro; Paola Iovino; Antonella Santonicola; Carolina Ciacci
Journal:  Gastroenterol Res Pract       Date:  2017-08-07       Impact factor: 2.260

5.  Patient Preference and Physician Perceptions of Patient Preference for Oral Pharmaceutical Formulations: Results from a Real-Life Survey.

Authors:  Lara MacKenzie-Smith; Paolo Marchi; Helen Thorne; Susan Timeus; Ryan Young; Perrine Le Calvé
Journal:  Inflamm Intest Dis       Date:  2018-10-11

6.  Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study.

Authors:  Juan Lasa; Gustavo Correa; Claudia Fuxman; Laura Garbi; Maria Eugenia Linares; Pablo Lubrano; Astrid Rausch; Martin Toro; Martin Yantorno; Ignacio Zubiaurre; Laurent Peyrin-Biroulet; Pablo Olivera
Journal:  Gastroenterol Res Pract       Date:  2020-01-17       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.